Eloxx Pharmaceuticals, Inc. Asset Resilience Ratio
Eloxx Pharmaceuticals, Inc. asset resilience ratio. Eloxx Pharmaceuticals, Inc. (ELOX) has an Asset Resilience Ratio of 16.96% as of June 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Eloxx Pharmaceuticals, Inc. to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Eloxx Pharmaceuticals, Inc. (2004–2019)
Asset resilience ratio of Eloxx Pharmaceuticals, Inc. from 2004 to 2019. This chart shows how Eloxx Pharmaceuticals, Inc.'s Asset Resilience Ratio has changed over time. Read Eloxx Pharmaceuticals, Inc. debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Eloxx Pharmaceuticals, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ELOX current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $6.77 Million | 16.96% |
| Total Liquid Assets | $6.77 Million | 16.96% |
Asset Resilience Insights
- Good Liquidity Position: Eloxx Pharmaceuticals, Inc. maintains a healthy 16.96% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Eloxx Pharmaceuticals, Inc. Industry Peers by Asset Resilience Ratio
Compare Eloxx Pharmaceuticals, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Eloxx Pharmaceuticals, Inc. Asset Resilience Ratio by Year (2004–2019)
Eloxx Pharmaceuticals, Inc. asset resilience ratio by year from 2004 to 2019. The table below shows the annual Asset Resilience Ratio data for Eloxx Pharmaceuticals, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 57.31% | $33.78 Million | $58.95 Million | +42.57pp |
| 2009-12-31 | 14.74% | $1.05 Million | $7.12 Million | +10.04pp |
| 2008-12-31 | 4.70% | $500.00K | $10.64 Million | -2.83pp |
| 2007-12-31 | 7.53% | $250.00K | $3.32 Million | -16.52pp |
| 2006-12-31 | 24.04% | $850.00K | $3.54 Million | -40.44pp |
| 2005-12-31 | 64.48% | $3.94 Million | $6.11 Million | -11.32pp |
| 2004-12-31 | 75.80% | $3.95 Million | $5.21 Million | -- |
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney dis… Read more